ASCO 2015 | Design and results of pacritinib for myelofibrosis trial (PERSIST-1)

Jean-Jacques Kiladjian

Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.

Share this video